CAR-T – Page 4 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2022-04-08

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

CD19 CAR T-cell therapy is effective at achieving durable remission for relapsed/refractory ALL across cytogenetic risk groups. CD19 CAR T-cell treatment results for patients with high-risk cytogenetics including Ph+, Ph-like, and KMT2A-rearranged ALL are encouraging. Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of relapsed/refractory B-acute lymphoblastic leukemia (ALL). However, case reports suggested differential

No Comments InCAR-T

PIER MARIA FORNASARI
2022-04-06

CAR T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein (NAP) from Helicobacter pylori to better fight cancer

Immunotherapy is increasingly becoming a successful way to treat cancer. Researchers at Uppsala University have now developed armed CAR-T cells that reinforce the immune defense against cancer and that could increase the possibilities to successfully treat solid tumors. The study has been published in the journal Nature Biomedical Engineering. The use of immunotherapy to treat cancer

No Comments InCAR-T

PIER MARIA FORNASARI
2022-03-30

Penn Researchers Shorten Manufacturing Time for CAR T Cell Therapy

A new approach allowed scientists to alter immune cells within 24 hours versus the standard of up to two weeks A new approach from Penn Medicine researchers could cut the time it takes to alter patients’ immune cells for infusion back into the body to find and attack cancer. The cell manufacturing process for this type of

No Comments InCAR-T

PIER MARIA FORNASARI
2022-03-30

In animal study, implant churns out CAR-T cells to combat cancer

Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T cells for attacking cancerous tumors. In a proof-of-concept study involving lymphoma in mice, the researchers found that treatment with the implants was faster and more effective than conventional CAR-T cell

No Comments InCAR-T

PIER MARIA FORNASARI
2022-03-26

Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17 CAR T cells without toxicity to normal tissues

Chimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and lymphomas, but there are no successful immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal cancers (GICs) yet. Researchers at Penn Medicine have discovered that CAR-T cells directed to a tumor antigen, CDH17, a cell surface marker expressed on both NETs and GICs but also

No Comments InCAR-T

PIER MARIA FORNASARI
2022-03-17

Cardiac damage as a side effect of CAR-T cell cancer therapy

CAR-T-cell cancer therapy uses special T-cells that are specifically directed towards tumor antigens, the so-called (CAR)-T-cells. These cells trigger a targeted immune response that helps the body recognize and fight cancer cells. But, like other cancer therapies, the treatment can cause unwanted side effects, such as affecting heart function. Scientists from the Medical Faculty of the University

No Comments InCAR-T

PIER MARIA FORNASARI
2022-03-01

CAR-based therapies an opportunity for immuno-medicine beyond cancer: a review published on Nature Metabolism

CAR T therapy has had enormous impact in some areas of oncology, and notable efforts are underway to extend the success to additional forms of cancer. However, the use of engineered T cells may be evenmore attractive for disorders other than cancer for several reasons. This review analyses different opportunities and future directions. First, for

No Comments InCAR-T

PIER MARIA FORNASARI
2022-02-21

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment: a review published on Frontiers

In this review, it’s provided an overview of the major mechanisms used by tumor cells to evade immune defenses and are critically exposed the most optimistic engineering strategies to make CAR-T cell therapy a solid option for solid tumors. CAR-T cell based cell therapy is a moving field, which showed impressive results in hematopoietic cancer

No Comments InCAR-T

PIER MARIA FORNASARI
2022-02-06

Study of Penn Patients with Decade-Long Leukemia Remissions after CAR T Cell Therapy Reveals New Details About Persistence of Personalized “Living Drug” Cells

Two patients represent longest-known CAR T cell response to date, providing insight into treatment effects and outcomes In the summer of 2010, Bill Ludwig and Doug Olson were battling an insidious blood cancer called chronic lymphocytic leukemia (CLL). They’d both received numerous treatments, and as remaining options became scarce, they volunteered to become the first

No Comments InCAR-T

PIER MARIA FORNASARI
2022-01-25

Removing Cancer “Sugar Shield” inproves the efficacy of CAR-T cells

Cancer cells increase the synthesis of sugars, that once exposed on the surface create a “shield” capable of hindering the immune system. According to a study published today in Science Translational Medicine, this shield could explain, at least in part, the reduced efficacy of CAR T cell therapies in solid tumors. The researchers also found a way to

No Comments InCAR-T

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category CAR-T

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

CAR T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein (NAP) from Helicobacter pylori to better fight cancer

Penn Researchers Shorten Manufacturing Time for CAR T Cell Therapy

In animal study, implant churns out CAR-T cells to combat cancer

Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17 CAR T cells without toxicity to normal tissues

Cardiac damage as a side effect of CAR-T cell cancer therapy

CAR-based therapies an opportunity for immuno-medicine beyond cancer: a review published on Nature Metabolism

Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment: a review published on Frontiers

Study of Penn Patients with Decade-Long Leukemia Remissions after CAR T Cell Therapy Reveals New Details About Persistence of Personalized “Living Drug” Cells

Removing Cancer “Sugar Shield” inproves the efficacy of CAR-T cells